Top in GI: Colorectal cancer screening, new trial for celiac disease therapy

An expert’s discussion about a colorectal cancer screening test that showed greater than 90% sensitivity was the top story in gastroenterology last week.

A video about a phase 3 trial that will investigate the potential role of larazotide acetate (9 Meters Biopharma) in patients with celiac disease was another top story.

Find these and more of last week’s top stories in gastroenterology below:

Geneoscopy RNA-FIT has high sensitivity for colorectal cancer

In this exclusive video, George Catinis, MD, medical director at the New Orleans Research Institute, discusses the efficacy of an RNA-FIT colorectal cancer screening test developed by Geneoscopy. Watch video.

Beyond Celiac, 9 Meters partner for trial recruitment

Alan M. Ehrlich, MD, of University of Massachusetts Medical School, discusses the partnership between Beyond Celiac and 9 Meters Biopharma to recruit patients for a clinical trial that will explore larazotide acetate for patients with celiac disease who continue to experience gastrointestinal symptoms while following a gluten-free diet. Watch video.

Mailed outreach, inreach effective for HCV screening

A combination of inreach and mailed outreach was an effective hepatitis C screening strategy among hard-to-reach populations, according to study results. Read more.

The Rome Criteria and What’s Next for Rome V

In this Gut Talk podcast, Douglas A. Drossman, MD, discusses his path into medicine, the history and influence of brain-gut interactions and what gastroenterologists can expect for Rome V criteria. Listen to podcast.

More clinical evidence needed before recommending probiotics

In this video, Colleen Cutcliffe, PhD, CEO and co-founder of Pendulum Therapeutics, talks about the latest findings regarding the microbiome. Watch video.